Sun Hechen, Zhang Lening, Zhao Nan, Xin Hua
Department of Thoracic Surgery, China-Japan Union Hospital of Jilin University, Changchun 130031, PR China.
ACS Omega. 2024 Feb 9;9(7):8425-8433. doi: 10.1021/acsomega.3c09619. eCollection 2024 Feb 20.
Lung cancer poses a significant threat to human health. Surgical intervention is the preferred treatment modality for lung cancer, but a large number of patients are deprived of the opportunity for surgery for various reasons and are compelled to undergo radiotherapy and chemotherapy, which entail systemic adverse reactions. In recent years, with the advancement of nanomedicine, chemodynamic therapy (CDT) based on free radicals has been extensively investigated. In this study, we fabricated copper-citrate-chitosan composite nanoparticles (CuCC NPs) by encapsulating copper-citrate complexes with natural chitosan polymers, resulting in a substantial reduction in the biotoxicity of copper ions. The CuCC NPs selectively accumulated in tumor tissues through the enhanced permeability and retention effect (EPR) and gradually degraded within the acidic and glutathione (GSH)-rich microenvironment of the tumor, thereby releasing the loaded copper ions. Through CDT, the copper ions converted the overexpressed hydrogen peroxide (HO) in the tumor tissue into hydroxyl radicals (•OH), leading to the eradication of tumor cells. In animal experiments, CuCC NPs exhibited remarkable efficacy in CDT. Further histopathological and hematological analyses demonstrated that CuCC NPs could induce substantial apoptosis in tumor tissues while maintaining an extremely high level of safety.
肺癌对人类健康构成重大威胁。手术干预是肺癌的首选治疗方式,但大量患者因各种原因被剥夺了手术机会,不得不接受放疗和化疗,而这些治疗会带来全身性不良反应。近年来,随着纳米医学的发展,基于自由基的化学动力学疗法(CDT)得到了广泛研究。在本研究中,我们通过用天然壳聚糖聚合物包裹柠檬酸铜络合物制备了柠檬酸铜-壳聚糖复合纳米粒子(CuCC NPs),从而大幅降低了铜离子的生物毒性。CuCC NPs通过增强的渗透和滞留效应(EPR)选择性地在肿瘤组织中积累,并在肿瘤的酸性和富含谷胱甘肽(GSH)的微环境中逐渐降解,从而释放负载的铜离子。通过CDT,铜离子将肿瘤组织中过表达的过氧化氢(HO)转化为羟基自由基(•OH),导致肿瘤细胞被根除。在动物实验中,CuCC NPs在CDT中表现出显著疗效。进一步的组织病理学和血液学分析表明,CuCC NPs可诱导肿瘤组织大量凋亡,同时保持极高的安全性。
ACS Biomater Sci Eng. 2021-4-12
ACS Appl Mater Interfaces. 2021-12-1
Naunyn Schmiedebergs Arch Pharmacol. 2025-6-27
Int J Nanomedicine. 2025-1-18
Int J Nanomedicine. 2025-1-4
Nanomaterials (Basel). 2024-8-23
BME Front. 2023-5-18
Signal Transduct Target Ther. 2023-8-7
Chemistry. 2023-7-26
CA Cancer J Clin. 2023-1
Signal Transduct Target Ther. 2022-11-23
Nat Rev Clin Oncol. 2023-1
Chin Med J (Engl). 2022-2-9
Semin Cancer Biol. 2022-11